Clinical efficacy of combination therapy with continuous intravenous pumping of Endostar and SOX regimen in advanced primary carcinoma of the liver
10.3969/j.issn.1006-5725.2016.17.037
- VernacularTitle:持续静脉泵注恩度联合SOX方案治疗原发性肝癌
- Author:
Jin SU
;
Xinhua XU
;
Kezhi SHI
;
Fang YI
;
Yang LIU
- Publication Type:Journal Article
- Keywords:
Primary carcinoma of the liver;
S-1;
Oxaliplatin;
Endostar
- From:
The Journal of Practical Medicine
2016;32(17):2908-2911
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of combination therapy of Endostar and oxaliplatin plus S-1 ( SOX regimen) in patients with advanced Primary carcinoma of the liver. Methods 32 advanced primary liver cancer patients admitted from February 2012 to August 2014 were assigned to SOX regimen as systemic chemotherapy: oxaliplatin 130 mg/m2 iv d1; S-1 (80 ~ 120 mg, twice-daily) for 14 days; 150 mg Endostar which was dissolved in 210 mL normal saline for 120 h durative transfusion. Treatment was repeated every 21 days. Objective clinical efficacy and adverse effect was assessed every 2 cycles. Serum alpha fetoprotein (AFP) level was also monitored according to the schedule. Results All 32 patients were available to be assessed, the objective response rate (ORR), disease control rate (DCR) ,the clinical benefit response rates (CBR), 1 year survival rate was 15.6%, 46.9%, 56.3%, 58.3% respectively. The serum AFP respond rate was 19.4%. Major adverse effects were myelosuppression and fatigue , mostly graded at 1 ~ 2. There were no treatment-related death. Conclusions These preliminary results suggest that continuous intravenous pumping of Endostar combined with SOX regimen could provide survival benefits with tolerable adverse effects.
